PharmaVentures Acts As Advisor to Plethora Solutions in deal with Recordati

OXFORD, UK, October 1st, 2014

PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature ejaculation.

Under the terms of the agreement Plethora are expected to receive upfront and milestone payments of up to €46 million plus royalties.

Stephen Waterman, Vice President, who led the PharmaVentures team on the deal commented: "We are delighted to have worked with Plethora on the deal terms of this important licensing agreement”.

Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “We would like to congratulate Plethora on their licensing agreement with Recordati”.

- ends -

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures Capital Limited is a wholly owned subsidiary of PharmaVentures Limited. All regulated activities are delivered through PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (741356). Pharma Ventures Capital Limited undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.